Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

ORIC Pharmaceuticals, Inc. (ORIC)

6.13   0.28 (4.79%) 01-27 16:00
Open: 5.82 Pre. Close: 5.85
High: 6.18 Low: 5.82
Volume: 145,328 Market Cap: 269(M)

Technical analysis

as of: 2023-01-27 4:46:53 PM
Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time.
Target: Six months: 7.96     One year: 9.3
Support: Support1: 4.42    Support2: 2.94
Resistance: Resistance1: 6.82    Resistance2: 7.96
Pivot: 6.03
Moving Average: MA(5): 6.14     MA(20): 5.97
MA(100): 3.85     MA(250): 4.5
MACD: MACD(12,26): 0.4     Signal(9): 0.5
Stochastic oscillator: %K(14,3): 39.9     %D(3): 46.3
RSI: RSI(14): 57.9
52-week: High: 9.6  Low: 2.35
Average Vol(K): 3-Month: 1,019 (K)  10-Days: 338 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ORIC ] has closed below upper band by 42.8%. Bollinger Bands are 10.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.18 - 6.22 6.22 - 6.26
Low: 5.74 - 5.78 5.78 - 5.82
Close: 6.06 - 6.13 6.13 - 6.19

Company Description

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Headline News

Sat, 28 Jan 2023
SCSU Accelerator to assist small businesses - SCNow

Fri, 27 Jan 2023
ORIC Pharmaceuticals, Inc.'s (NASDAQ:ORIC) latest 12% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance UK

Tue, 24 Jan 2023
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Simply Wall St

Fri, 13 Jan 2023
Regulator demands answers over 'irregularities' in Perth Aboriginal ... - WAtoday

Fri, 13 Jan 2023
Contracts awarded for second phase of Orkney research campus -

Fri, 13 Jan 2023
LCWU ORIC ranked 1st among women’s varsities - The News International

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 40 (M)
Shares Float 28 (M)
% Held by Insiders 14.9 (%)
% Held by Institutions 72.2 (%)
Shares Short 2,440 (K)
Shares Short P.Month 2,640 (K)

Stock Financials

EPS -2.22
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.42
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -19.8
Return on Equity (ttm) -36
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.19
Qtrly Earnings Growth 0
Operating Cash Flow -76 (M)
Levered Free Cash Flow -42 (M)

Stock Valuations

PE Ratio -2.78
PEG Ratio 0
Price to Book value 1.12
Price to Sales 0
Price to Cash Flow -3.19

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.